Organic growth of 1.4%, with pricing of 3.4% and real internal growth (RIG) of -2.0%. Foreign exchange decreased sales by 6.7%. Net divestitures had a negative impact of 0.6%. Mark Schneider, Nestle CEO, commented: “We had expected a slow start and see a strong rebound in RIG in the second quarter with reliable delivery for the remainder of the year. A wide range of growth initiatives across the Group are now starting to deliver. In North America, we have stepped up our innovation intensity and commercial activities, primarily in frozen food, which lost ground in the first quarter. The integration plan for Nestle Health Science’s vitamins, minerals and supplements business is on track, with the turning point expected in the second quarter and strong growth thereafter. Nestle’s top priorities remain to execute with excellence, leverage our science and nutrition expertise and drive growth with our billionaire brands. We reiterate our 2024 guidance and look ahead with confidence.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRGY:
- VGK vs. EZU: Which Is the Better European Stock ETF?
- Nestle price target lowered to CHF 84.50 from CHF 86 at Jefferies
- Nestle granted orphan status for fatty acid oxidation treatment
- European Stocks: Unnoticed Records, Overlooked Opportunities
- Nestle price target lowered to CHF 116 from CHF 122 at Berenberg